RE:RE:1St quarter BTDYes back in an August 29 NR ,"The Company has submitted a pre-BTD submission to the FDA and based on the FDA’s feedback, the Company is currently working with the CSSs, a biostatistics organization and a regulatory organization to update the pre-BTD with clinical data clarifications identified by the FDA. The Company plans to resubmit the pre-BTD submission to the FDA in late 3Q2023 / early 4Q2023 for FDA review of these clarifications. Once the pre-BTD submission has been accepted by the FDA, the Company plans to compile a BTD submission for review by the FDA in support of the grant of a BTD approval in 4Q2", it looks like we are back at it or FDA wanted more info, the only thing that changed was the wording of quarters, pushed back 2 quarters for possibly not having time to get the analysis done correctly